Table 3 TRAEs summary

From: Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

 

Monotherapy cohort (n = 26)

TRAE Summary, n (%)

 TRAEs of any grade

14 (53.8)

 Grade 3-4 TRAEs

5 (19.2)

 Leading to Dose Reduction or Interruption

5 (19.2)

 Leading to Drug Discontinuation

1 (3.8)

 Leading to Death

0

Most Common (≥10%) TRAEs, n (%)

Any Grade

Grade 3-4

 Alanine aminotransferase increased

8 (30.8)

3 (11.5)

 Aspartate aminotransferase increased

7 (26.9)

2 (7.7)

 Diarrhea

3 (11.5)

1 (3.8)

 Blood bilirubin increased

3 (11.5)

0

 

Combination cohort (n = 42)

TRAE Summary, n (%)

Garsorasib

Cetuximab

TRAEs of any grade

42 (100)

Grade 3-4 TRAEs

6 (14.3)

 Leading to Dose Reduction or Interruption

4 (9.5)

11 (26.2)

 Leading to Drug Discontinuation

0

1 (2.4)

 Leading to Death

0

0

Most Common (≥10%) TRAEs, n (%)

Any Grade

Grade 3-4

 Rash

30 (71.4)

2 (4.8)

 Aspartate aminotransferase increased

15 (35.7)

0

 Paronychia

14 (33.3)

0

 Alanine aminotransferase increased

13 (31.0)

0

 Blood bilirubin increased

9 (21.4)

0

 Dry skin

7 (16.7)

0

 Proteinuria

6 (14.3)

0

 Skin fissures

6 (14.3)

0

 Dermatitis acneiform

5 (11.9)

1 (2.4)

 Nausea

5 (11.9)

0

 Pruritus

5 (11.9)

0

Back to article page